Severe and Asymptomatic Data Could Give Moderna’s COVID-19 Vaccine Slight Edge Over Pfizer’s

Moderna, Inc.’s COVID-19 vaccine will head into its 17 December US Food and Drug Administration advisory committee review with more solid data on its impact on severe disease than competitor Pfizer Inc./BioNTech SE’s had when that vaccine went in front of the same committee last week. Moderna also has some preliminary data on its vaccine’s ability to prevent transmission of the virus, of which Pfizer had none.

With an overall similar efficacy and safety profile to Pfizer’s product, Moderna is all but guaranteed to receive the second...